Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

• by Mark Davis

• May 6, 2026

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

• May 5, 2026

• 5 min

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

• by The ASCO Post Staff

• May 4, 2026

• 3 min

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

• by The ASCO Post Staff

• May 4, 2026

• 4 min